Cargando…
siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies?
Acute viral respiratory tract infections (AVRIs) are a major burden on human health and global economy and amongst the top five causes of death worldwide resulting in an estimated 3.9 million lives lost every year. In addition, new emerging respiratory viruses regularly cause outbreaks such as SARS‐...
Autores principales: | Mehta, Aditi, Michler, Thomas, Merkel, Olivia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995229/ https://www.ncbi.nlm.nih.gov/pubmed/33506607 http://dx.doi.org/10.1002/adhm.202001650 |
Ejemplares similares
-
Therapy of Respiratory Viral Infections with Intranasal siRNAs
por: Barik, Sailen, et al.
Publicado: (2014) -
Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread
por: Ambike, Shubhankar, et al.
Publicado: (2021) -
Hotspot siRNA Confers Plant Resistance against Viral Infection
por: Mohamed, Atef, et al.
Publicado: (2022) -
PD-L1 Silencing in Liver Using siRNAs Enhances Efficacy of Therapeutic Vaccination for Chronic Hepatitis B
por: Bunse, Till, et al.
Publicado: (2022) -
Viral targets for vaccines against COVID-19
por: Dai, Lianpan, et al.
Publicado: (2020)